Semaglutide + Cagrilintide Peptide Blend – Research Use Only
5MG/5MG
 
Description:
This blend combines Semaglutide, a GLP-1 receptor agonist, with Cagrilintide, an amylin analogue. Both peptides have been studied individually for their roles in metabolic regulation, appetite control, and weight management models, and current research suggests their combination may have synergistic effects in regulating food intake, energy balance, and metabolic markers.
 
Background:
Semaglutide is a GLP-1 analogue that has been researched for its effects on glucose regulation, insulin sensitivity, and appetite suppression.
Cagrilintide is a long-acting amylin analogue studied for its ability to modulate satiety, gastric emptying, and weight regulation.
When combined, these peptides provide a unique research platform for exploring dual-hormone regulation of metabolism. Studies have indicated that the Semaglutide + Cagrilintide pairing may enhance satiety and metabolic outcomes beyond single-peptide models.
 
Potential Areas of Research:
Dual hormone modulation of appetite and satiety
Weight management and energy balance models
Glucose metabolism and insulin sensitivity research
Comparative studies of GLP-1 agonist vs. combination therapy
Research on gastric emptying and nutrient absorption pathways
 
Molecular Formula & Weight:
Semaglutide: C₁₈₇H₂₉₁N₄₅O₅₉ | ~4113 g/mol
Cagrilintide: C₁₈₆H₂₈₈N₅₀O₅₈S | ~4000+ g/mol (approximate)
 
Disclaimer:
This peptide blend is provided strictly for laboratory research purposes only. It is not a drug, food, or cosmetic, and must not be used for human consumption, medical, or veterinary purposes.